News & Views
Agreement to Progress ADC Candidates to Clinical Use
Nov 10 2017 Read 291 Times
IONTAS, a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, is collaborating with antibody drug conjugate (ADC) development company Glythera on research to progress ADCs for difficult-to-treat cancers. As part of the agreement IONTAS will generate human antibodies against specified targets for proof-of-concept studies. Glythera will have an option for exclusive, worldwide rights to resulting antibodies for the development of ADCs alongside its proprietary conjugation platform, PermaLink® and its in-house portfolio of novel toxins, with an intention to nominate its first clinical ADC candidate by 2019. IONTAS will receive undisclosed development and clinical milestone payments on each of the ADCs.
Dr John McCafferty, CEO at IONTAS, commented: “This Agreement reflects the ambition of IONTAS to establish broader relationships with partners for multiple antibody deals using our proprietary technology platforms. We believe our expertise and efficiency in antibody discovery will help Glythera with their ultimate short term goal of being in clinic by 2019.”
Dr Dave Simpson, CEO at Glythera, said: “We identified IONTAS as the ideal partner for antibody discovery, due to their proprietary phage display technology and libraries, providing the potential for development of multiple antibodies. The combination of IONTAS’ experience and expertise, with our proven PermaLink platform, will support our mission to target difficult-to-treat tumours and progress towards the clinic.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Monitoring Airborne Molecular Contamination in Indoo...
View all digital editions
Jun 27 2018 Tokyo, Japan
Jul 08 2018 Baltimore, MD, USA
Jul 29 2018 Chicago, IL, USA
Jul 29 2018 Washington DC, USA
Aug 05 2018 Baltimore, MD, USA